Infinimmune, a biotechnology company pioneering antibody discovery and design, announced a collaboration with MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA), to apply Infinimmune’s human-first antibody discovery platform to identify and develop antibody candidates against multiple undisclosed targets designated by MSD.
